Head & Neck/Thyroid Cancers
News
Advice from the front lines: How cancer centers can cope with COVID-19
The medical director of the Seattle Cancer Care Alliance offers advice for cancer centers dealing with COVID-19.
News
Maintaining cancer care in the face of COVID-19
Oncologists are moving cancer patients to other hospitals, reevaluating the need for cancer treatments, and embracing telemedicine to protect...
News
Blood test might detect multiple cancer types, study suggests
The test, which uses methylation patterns in plasma cell-free DNA, had specificity and sensitivity approaching those needed for population-based...
News
Cancer care and COVID-19 in Seattle, the first U.S. epicenter
Article
How is oncology adapting to COVID-19?
News
Disruptions in cancer care in the era of COVID-19
Conference Coverage
RT plus checkpoint blockade active in head and neck cancer
At 2 years, the progression-free survival rate was 71%, and the overall survival rate was 75%.
News
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors
Two-thirds of patients with advanced renal cell carcinoma had a clinical response to the TKI/immune checkpoint inhibitor combination.
News
Multimodal therapies almost double survival in anaplastic thyroid cancer
CHICAGO – One cancer center’s experience shows that a targeted, multidisciplinary approach makes a difference.
